Corcept's Insiders Are Selling Millions—Is the FDA Warning Just the Beginning?

The public drama is loud. A class action lawsuit alleges Corcept misled investors about FDA concerns with its key drug, relacorilant, between October 2024 and December 2025. The complaint claims the company falsely said the drug was "approaching approval" while knowing the FDA had serious doubts about its clinical data. That's the headline risk. But the smart money is looking past the legal filings to the real-time signals from those who know the company best.

Over the last 90 days, insiders have executed six transactions, all sales totaling over $4 million. That's not a minor tax payment; it's a coordinated exit. The stock has declined nearly 59% in that same period, a brutal drop that includes the lawsuit announcements. When the people with the most skin in the game are selling en masse, it often signals they see a problem the lawsuit merely confirms. It's a classic flight of capital.

This isn't about a single bad quarter. It's about a pattern. The lawsuit focuses on a specific period of alleged misrepresentation, but the insider selling and the stock's collapse cover a broader timeframe. The smart money is fleeing, not fighting. That suggests the legal allegations may be a symptom of deeper operational or regulatory problems, not a standalone risk. If the company were truly on a solid path, you'd expect insiders to be buying, or at least holding steady, not cashing out over $4 million in a few months. The whale wallet is telling a different story than the press release.

Skin in the Game: Who's Buying, Who's Selling?

The numbers tell a clear story of disengagement. Over the last 90 days, Corcept has seen six insider transactions, all sales totaling more than $4 million. That's not a trickle; it's a coordinated exit by those who should know the company's true value. The largest single seller was Chief Development Officer William Guyer, who executed multiple planned and proposed sales of 20,000 shares each in January and February. His trades, which included a proposed sale of 91,000 shares in March, represent a significant portion of his holdings and signal a lack of conviction in the near-term outlook.

Then there's Director James N. Wilson. He made a gift of 28,000 shares on March 13. While a gift is a legitimate transfer, it's not an investment. The filing shows he transferred existing holdings, which means he's reducing his personal stake without adding new capital. In a company facing a major lawsuit and a 59% stock decline, such a move by a board member is a neutral signal at best, and a vote of no confidence at worst.

The broader picture of insider ownership is also telling. The company reports insider ownership at 26.85% of shares outstanding. That's a high concentration, which should, in theory, align interests. But the recent selling activity-where the net number of insiders buying is a stark -4-reveals a critical disconnect. When insiders collectively sell, it suggests they see risks the public is missing. The smart money isn't buying; it's getting out.

The bottom line is one of misaligned incentives. A CDO selling his shares while the company is in a legal and regulatory firestorm, and a director gifting his stake, are not the actions of people betting the company's future. They are actions of people securing their gains. The skin in the game is being removed, leaving retail investors to bear the brunt of the fallout.

The Smart Money's Move: Institutional Accumulation or Panic?

The insider selling tells a clear story. But what about the broader institutional base? Are they following the same flight, or are they seeing a buying opportunity in the chaos?

The company's own data presents a confusing headline. Corcept's Insider Sentiment Score indicates a high level of insider accumulation relative to its peers. That score, generated by a complex model, is supposed to flag companies where insiders are buying. Yet it directly contradicts the hard evidence: over the last 90 days, the net number of insiders buying is a stark -4, and they've sold shares worth over $4 million. This disconnect suggests the model may be outdated or overly simplistic, failing to capture the recent, coordinated exit. In other words, the score is a ghost of past behavior, not a signal for today.

More importantly, there is no evidence of significant institutional accumulation. The provided evidence does not include any 13F filings or data showing large funds buying shares. The institutional stance remains a black box. In a market where 13F filings are the primary window into smart money moves, the absence of data is telling. It means we cannot confirm whether large investors are buying the dip or, like the insiders, bailing out.

The stock's brutal 59% decline in the past three months, however, points to a major shift in sentiment. That kind of drop is rarely driven by a single lawsuit; it reflects a wholesale reassessment of risk. The FDA concerns, the insider selling, and the legal overhang have likely triggered a wave of selling from funds that once held the stock. The smart money may have already moved, leaving the current price action to be driven by retail traders and short-term speculators.

The bottom line is one of uncertainty, but the weight of evidence leans toward panic. When the people with the most skin in the game are selling, and institutional filings show no counter-accumulation, it suggests the broader market is fleeing. The lawsuit may be the spark, but the fire was already burning. For now, the smart money's move is clear: it's getting out.

Catalysts and What to Watch

The real test for Corcept's thesis is coming fast. The lawsuit is a symptom, but the catalysts ahead will confirm whether the insider-driven distress is justified or if there's a path to recovery. Watch these three events closely.

First, the FDA's final decision on the NDA for relacorilant is the ultimate arbiter. The lawsuit alleges the company misrepresented the agency's stance during the class period, claiming the drug was "approaching approval" while knowing the FDA had serious concerns about its clinical data. The final ruling will either validate those allegations or clear the company. A rejection would confirm the insider selling was prescient. A positive decision, while a potential relief rally, would do little to restore trust after the alleged misrepresentations and the stock's 59% collapse.

Second, monitor the insider trading ledger for any shift. The pattern of six sales totaling over $4 million in 90 days is a powerful signal of disengagement. The next move matters. A halt in selling, or better yet, a return to buying by executives like Chief Development Officer William Guyer, would be a positive signal that some insiders see value in the current price. But given the lawsuit and the stock's decline, a continuation of selling would reinforce the thesis that the smart money sees no near-term upside.

Finally, watch the stock's reaction to the class action lead plaintiff deadline on April 21, 2026. The lawsuit is in its early stages, but the deadline is a near-term event that could trigger volatility. The stock may react to the filing of motions or any developments in the lead plaintiff selection process. More importantly, any subsequent court rulings on the lawsuit's merits will provide a legal verdict on the allegations of misrepresentation. A favorable ruling for plaintiffs would likely pressure the stock further, while a dismissal would be a positive catalyst. For now, the smart money is getting out. The coming catalysts will show if they were right to flee.